<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343586</url>
  </required_header>
  <id_info>
    <org_study_id>STU00210472</org_study_id>
    <nct_id>NCT04343586</nct_id>
  </id_info>
  <brief_title>Blue Light Phototherapy</brief_title>
  <official_title>Development &amp; Preliminary Clinical Validation Blue Light Phototherapy Systems for T-Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>T-Cellerate LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and
      Grover's Disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">February 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of blue light therapy for patients with Grover's disease or psoriasis vulgaris</measure>
    <time_frame>Time Frame: 1 year</time_frame>
    <description>Demonstrate preliminary skin efficacy as demonstrated by clinical photo evaluation, patient reported outcomes with Dermatology Life Quality Index (DLQI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of blue light therapy for patients with Grover's disease or psoriasis vulgaris</measure>
    <time_frame>Time Frame: 1 year</time_frame>
    <description>Skin histopathology with both Grover's disease and psoriasis vulgaris.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of blue light therapy for patients with psoriasis vulgaris</measure>
    <time_frame>Time Frame: 1 year</time_frame>
    <description>We will be using the PSORIASIS AREA AND SEVERITY INDEX (PASI) scale to determine the severity of psoriasis vulgaris before and after receiving blue light treatments.
http://www.bad.org.uk/shared/get-file.ashx?id=1654&amp;itemtype=document</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess user experience</measure>
    <time_frame>Time Frame: 1 year</time_frame>
    <description>• Obtain user comfort and experience with phototherapy system using psychometric survey.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular analysis of Blue light phototherapy</measure>
    <time_frame>Time Frame: 1 year</time_frame>
    <description>• Elucidate keratinocyte and skin T-cell expression, and viability with blue light phototherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular analysis of Blue light phototherapy</measure>
    <time_frame>Time Frame: 1 year</time_frame>
    <description>Elucidate changes in circulatory T-cells based on flow cytometry and serum cytokines with blue light therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Grover's Disease</condition>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adult treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults enrolled in the study will receive treatment (blue light phototherapy) on one area of their body affected by psoriasis or Grover's disease. The treatment area (restricted by size of the device) will be compared to untreated areas affected by disease on the same patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blue light phototherapy</intervention_name>
    <description>Phototherapy- Wavelength: 417±15 nm</description>
    <arm_group_label>Adult treatment arm</arm_group_label>
    <other_name>DusaPharma Blu-U model 4170</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient's aged 18-89 at time of enrollment

          2. Previous diagnosis of psoriasis vulgaris or Grover's disease

        Exclusion Criteria:

          1. All Groups: Subjects who are younger than 18 years of age or older than 90 years of
             age

          2. Patients who have received topical or systemic treatment within the prior 2 weeks of
             planned phototherapy

          3. Patients prescribed any of the following drugs for issues not related to their
             psoriasis or Grover's disease

               -  topical steroids

               -  calcineurin inhibitors

               -  methotrexate

               -  retinoids

               -  biologic agents

          4. Unable to schedule phototherapy sessions

          5. We will not recruit the following populations: adults unable to consent, individuals
             who are not yet adults (infants, children, teenagers), pregnant women, prisoners and
             other vulnerable populations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuai Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dermatology CTU</last_name>
    <phone>312-503-5944</phone>
    <email>DermSensors@northwestern.edu</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Shuai (Steve) Xu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

